{"groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"FG000","title":"Tisagenlecleucel - Main Cohort"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"FG001","title":"Tisagenlecleucel Cohort A"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"12"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"1"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"0"}],"type":"Subject decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"99"},{"groupId":"FG001","numSubjects":"16"}],"comment":"Started = Infused","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"3"}],"comment":"Completed = Study follow-up completed","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"13"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"After informed consent/assent was obtained, and prior to infusion, participants underwent a routine lymphodepleting therapy, 14 to 5 days before CTL019 infusion.\n\nThere were 27 centers across 10 countries for this trial.","recruitmentDetails":"115 participants were infused in this study: 99 in the Main Cohort and 16 in Cohort A."}